PEDIATRICS Vol. 106 No. 5 November 2000, pp. 1103-1104
SPECIAL ARTICLE:
Is There More to Lung Development Than Steroids and Surfactant?
and
From the * Pediatric Pulmonary Unit and the
Pulmonary and
Critical Care Unit, § Departments of Medicine and Pediatrics,
Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts.
There has been a recent renaissance in the
field of lung development. More has been learned about how the lungs
are formed and how they grow in the last 10 years than in all the prior
years combined. Striking parallels have emerged between mouse models and actual human diseases and developmental defects. The following is a
brief review of our current understanding of the regulating factors and
their interactions.
One of the most interesting of the recent insights into pulmonary
molecular physiology occurred by pure serendipity. Pulmonary alveolar
proteinosis (PAP) is an extraordinary disease in which the lungs are
filled with a proteinaceous, lipid-rich material. Little was known
about the cause. Then oncologist Glenn Dranoff and
colleagues,1 attempting to identify molecules that could
be useful in enhancing tumor vaccines, created a knockout mouse of
granulocyte-macrophage colony-stimulating factor (GM-CSF).
Surprisingly, the mice had no abnormalities of immunity, but they were
born with lungs that resembled those of human patients with PAP.
Indeed, it appears that GM-CSF regulates the clearance of surfactant
from the lung by macrophages. Some patients with PAP actually have a
defect in the GM-CSF receptor. Fortunately, these new insights have
allowed for novel therapeutic interventions including recombinant
GM-CSF and possibly in the future, bone marrow transplantation to
replace abnormal lung macrophages.
In contrast to the research on PAP, other lines of investigation have
depended less on serendipity and more on a targeted approach to
identify the earliest progenitors of the embryonic lung. The lung bud
grows toward mesenchyme and subdivides in an orderly process known as
branching morphogenesis. Growth factors regulate this process. They are
secreted by the developing epithelium to act on the mesenchyme and visa
versa. Some of these factors are expressed in a clump of cells around
the budding trachea and they specify where the tracheal buds should
grow. Growth factors act on receptors to initiate a signaling cascade
that leads to the activation of proteins (transcription factors) that
upregulate the genes that control development.
The profile of growth factors changes at defined points during
development. A number of important growth factors were first identified
in the fruit fly, which has a primitive respiratory system. Despite the
differences when compared with the vertebrate respiratory system, the
mechanisms involved in the regulation of respiratory system development
in the fruit fly have illuminated our understanding of vertebrate lung
development. One fly growth factor is named branchless because tracheal
buds failed to grow when it was mutated. The branchless growth factor
is remarkably similar to mammalian FGF10 and FGF7, which seem to
fulfill very similar functions in the mouse.2 Deletion of
FGF10 or its receptor leads to abnormal bronchial development. On the
other hand, overexpression of FGF7 causes excess development of
premature bronchi and results in a condition similar to a human lung
malformation called cystic adenomatoid malformation (CAM). There are
concerns that CAM is a premalignant condition and this mouse model
produced by excess growth factor adds to this concern.
Connective tissue and cartilage surround the proximal airway. This
tissue is derived from the mesenchyme. As lung development proceeds and
respiratory bronchioles are formed, the connective tissue lining
becomes reduced thus facilitating gas exchange between air in the
alveolus and blood in the surrounding capillaries. A factor called
Sonic hedgehog (Shh) is secreted by the epithelium and acts on a
receptor in the mesenchyme, called patched (ptc) which in turn
activates transcription factors called Gli1, 2, and 3.3
This cascade maintains the mesenchymal coat. As lung development proceeds this pathway is down regulated. Mice with a knockout of Shh
have developmental defects of the foregut including tracheoesophageal fistulas. Interestingly, human mutations of Shh are associated with
holoprosencephaly. This condition has been associated with foregut
anomalies in some patients, suggesting that Shh is also active in the
development of the human foregut.
The most distal ends of the developing respiratory tree form
gas-exchange regions of the lung that includes the respiratory bronchioles, the alveolar ducts, and the alveoli. Alveologenesis occurs
in 2 distinct stages. A sac forms in the wall of the alveolar duct and
is further divided by septa into alveoli resulting in a dramatic
increase in the surface area for gas exchange. The myofibroblasts play
a critical role in septa formation by secreting elastin and collagen.
The myofibroblast number and secretory ability are regulated by
platelet-derived growth factor-A (PDGF-A), which is secreted by the
alveolar epithelium to act on the PDGF-A receptor on the myofibroblast.
When the PDGF-A gene is deleted in mice, septation does not occur and
the mice develop emphysema.4 On the other hand in fibrotic
lung disease, there are excess myofibroblasts and, consequently,
increased deposition of collagen. Retinoic acid, the active metabolite
of vitamin A, also regulates septation and alveolar formation. Retinoic
acid has been used to promote alveologenesis in rat models of
emphysema.5 New therapies are being designed to treat
emphysema based on our new understanding of molecular factors that
regulate development. These therapies combined with the use of
glucocorticoids may be useful in treating the very premature
lung.6
Finally, the identification of the earliest cells committed to
form the lung may help to isolate the airway and parenchymal stem
cells, if they exist. The purification and growth of these cells in
vitro would be an enormous boon to research in pulmonology. These cells
could be used for in vitro drug testing, as targets for gene therapy
vectors, and as the progenitor cells for tissue replacement therapies.
Given the lack of effective therapies for many pulmonary diseases and
the obvious problems with lung transplantation on a large scale, it is
likely that research into lung organogenesis will provide valuable
insights into human pulmonary disease and therapeutics.
![]()
ARTICLE
Top
Article
References
| |
FOOTNOTES |
|---|
Received for publication Mar 10, 2000; accepted Mar 10, 2000.
Address correspondence to T. Bernard Kinane, MD, Pediatric Pulmonary Unit, Vincent Burham Basement, 55 Fruit St, Massachusetts General Hospital, Boston, MA 02114. E-mail: kinane{at}helix.mgh.harvard.edu
| |
ABBREVIATIONS |
|---|
PAP, pulmonary alveolar proteinosis; GM-CSF, granulocyte-macrophage colony-stimulating factor; CAM, cystic adenomatoid malformation; Shh, Sonic hedgehog; ptc, patched; PDGF-A, platelet-derived growth factor A.
| |
REFERENCES |
|---|
|
|
|---|
-
Dranoff G,
Crawford AD,
Sadelain M,
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
Science.
1994;
264:713-716
[Abstract/Free Full Text] - Sutherland D, Samakovlis C, Krasnow MA Branchless encodes a Drosophila FGF homolog that controls tracheal cell migration and the pattern of branching. Cell. 1996; 87:1091-1101 [CrossRef][Medline]
- Pepicelli CV, Lewis PM, McMahon AP Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol. 1998; 8:1083-1086 [CrossRef][Medline]
- Bostrom H, Willetts K, Pekny M, PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell. 1996; 85:863-873 [CrossRef][Medline]
- Massaro GD, Massaro D Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997; 3:675-677 [CrossRef][Medline]
-
Muglia LJ,
Bae DS,
Brown TT,
Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice.
Am J Respir Cell Mol Biol.
1999;
20:181-188
[Abstract/Free Full Text]
Pediatrics (ISSN 0031 4005). Copyright ©2000 by the American Academy of Pediatrics
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




